Latest 3 stories · newest Oct 29, 2026
Bicycle Therapeutics announced that nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer, ahead of expected phase 2 trial updates and the anticipated initiation of a radioligand trial in 2027.
The company reported Q2 2026 financials with $510.1 million in cash, provided clinical update on nuzefatide during AACR, and expanded its Clinical Advisory Board.
Zelenectide pevedotin combined with pembrolizumab demonstrated response rates comparable to standard of care in metastatic urothelial cancer with approximately four-fold lower skin reactions and half the peripheral neuropathy rates. The data validation of Bicycle's technology platform could support …
The same BCYC feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/BCYC/newsSTART FREE